Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
Biliary tract cancers are a diverse and aggressive malignancy that carry a poor chance for curative treatment and significant associated mortality. Current first-line treatment only extends median overall survival to roughly 1 year and is associated with a significant adverse event profile. Recently...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-08-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848221115317 |
| _version_ | 1798040943001075712 |
|---|---|
| author | Daniel Walden Cody Eslinger Tanios Bekaii-Saab |
| author_facet | Daniel Walden Cody Eslinger Tanios Bekaii-Saab |
| author_sort | Daniel Walden |
| collection | DOAJ |
| description | Biliary tract cancers are a diverse and aggressive malignancy that carry a poor chance for curative treatment and significant associated mortality. Current first-line treatment only extends median overall survival to roughly 1 year and is associated with a significant adverse event profile. Recently, advancements in genetic sequencing have opened new avenues of targeted treatment. In cholangiocarcinoma, FGFR2 alterations have been shown to be present in roughly 10–15% of intrahepatic cholangiocarcinoma. Pemigatinib, a FGFR1–4 inhibitor, has been shown to significantly extend survival in the second-line setting to over 20 months in patients who harbor FGFR2 fusions. Here, we outline the development and future direction of pemigatinib and other FGFR2 inhibitors in the field of advanced biliary tract cancers. |
| first_indexed | 2024-04-11T22:14:38Z |
| format | Article |
| id | doaj.art-548a7a84476847ed89690ab490ca6767 |
| institution | Directory Open Access Journal |
| issn | 1756-2848 |
| language | English |
| last_indexed | 2024-04-11T22:14:38Z |
| publishDate | 2022-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-548a7a84476847ed89690ab490ca67672022-12-22T04:00:28ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482022-08-011510.1177/17562848221115317Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangementsDaniel WaldenCody EslingerTanios Bekaii-SaabBiliary tract cancers are a diverse and aggressive malignancy that carry a poor chance for curative treatment and significant associated mortality. Current first-line treatment only extends median overall survival to roughly 1 year and is associated with a significant adverse event profile. Recently, advancements in genetic sequencing have opened new avenues of targeted treatment. In cholangiocarcinoma, FGFR2 alterations have been shown to be present in roughly 10–15% of intrahepatic cholangiocarcinoma. Pemigatinib, a FGFR1–4 inhibitor, has been shown to significantly extend survival in the second-line setting to over 20 months in patients who harbor FGFR2 fusions. Here, we outline the development and future direction of pemigatinib and other FGFR2 inhibitors in the field of advanced biliary tract cancers.https://doi.org/10.1177/17562848221115317 |
| spellingShingle | Daniel Walden Cody Eslinger Tanios Bekaii-Saab Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements Therapeutic Advances in Gastroenterology |
| title | Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements |
| title_full | Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements |
| title_fullStr | Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements |
| title_full_unstemmed | Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements |
| title_short | Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements |
| title_sort | pemigatinib for adults with previously treated locally advanced or metastatic cholangiocarcinoma with fgfr2 fusions rearrangements |
| url | https://doi.org/10.1177/17562848221115317 |
| work_keys_str_mv | AT danielwalden pemigatinibforadultswithpreviouslytreatedlocallyadvancedormetastaticcholangiocarcinomawithfgfr2fusionsrearrangements AT codyeslinger pemigatinibforadultswithpreviouslytreatedlocallyadvancedormetastaticcholangiocarcinomawithfgfr2fusionsrearrangements AT taniosbekaiisaab pemigatinibforadultswithpreviouslytreatedlocallyadvancedormetastaticcholangiocarcinomawithfgfr2fusionsrearrangements |